Literature DB >> 15047603

Glucose regulates the expression of the farnesoid X receptor in liver.

Daniel Duran-Sandoval1, Gisèle Mautino, Geneviève Martin, Fréderic Percevault, Olivier Barbier, Jean-Charles Fruchart, Folkert Kuipers, Bart Staels.   

Abstract

An increased prevalence of hypertriglyceridemia and gallbladder disease occurs in patients with diabetes or insulin resistance. Hypertriglyceridemia is positively associated to gall bladder disease risk. The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor that plays a key role in bile acid and triglyceride homeostasis. The mechanisms controlling FXR gene expression are poorly understood. This study evaluated whether FXR gene expression is regulated by alterations in glucose homeostasis. FXR expression was decreased in livers of streptozotocin-induced diabetic rats and normalized upon insulin supplementation. Concomitantly with diabetes progression, FXR expression also decreased in aging diabetic Zucker rats. In primary rat hepatocytes, D-glucose increased FXR mRNA in a dose- and time-dependent manner, whereas insulin counteracted this effect. Addition of xylitol, a precursor of xylulose-5-phosphate, to primary rat hepatocytes increased FXR expression to a comparable level as D-glucose. Finally, expression of the FXR target genes, SHP and apolipoprotein C-III, were additively regulated by D-glucose and FXR ligands. This study demonstrates that FXR is decreased in animal models of diabetes. In addition, FXR is regulated by glucose likely via the pentose phosphate pathway. Dysregulation of FXR expression may contribute to alterations in lipid and bile acid metabolism in patients with diabetes or insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047603     DOI: 10.2337/diabetes.53.4.890

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  80 in total

1.  Inhibitory effects of bile acids and synthetic farnesoid X receptor agonists on rotavirus replication.

Authors:  Yunjeong Kim; Kyeong-Ok Chang
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 2.  Role of bile acids in the regulation of the metabolic pathways.

Authors:  Hiroki Taoka; Yoko Yokoyama; Kohkichi Morimoto; Naho Kitamura; Tatsuya Tanigaki; Yoko Takashina; Kazuo Tsubota; Mitsuhiro Watanabe
Journal:  World J Diabetes       Date:  2016-07-10

3.  Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats.

Authors:  Brian T Hawkins; Scott M Ocheltree; Kristi M Norwood; Richard D Egleton
Journal:  Neurosci Lett       Date:  2006-11-15       Impact factor: 3.046

Review 4.  Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease.

Authors:  Jeff L Staudinger; Kristin Lichti
Journal:  Mol Pharm       Date:  2007-12-27       Impact factor: 4.939

5.  Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation.

Authors:  Yuan Tian; Jingwei Cai; Wei Gui; Robert G Nichols; Imhoi Koo; Jingtao Zhang; Mallappa Anitha; Andrew D Patterson
Journal:  Drug Metab Dispos       Date:  2018-11-08       Impact factor: 3.922

6.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

Authors:  Yanqiao Zhang; Florence Ying Lee; Gabriel Barrera; Hans Lee; Charisse Vales; Frank J Gonzalez; Timothy M Willson; Peter A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-12       Impact factor: 11.205

7.  The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Luciano Adorini; Mark Pruzanski; Frank J Gonzalez; Pnina Scherzer; Linda Lewis; Shinobu Miyazaki-Anzai; Moshe Levi
Journal:  Am J Physiol Renal Physiol       Date:  2009-09-23

8.  Biomolecular signatures of diabetic wound healing by structural mass spectrometry.

Authors:  Kelly M Hines; Samir Ashfaq; Jeffrey M Davidson; Susan R Opalenik; John P Wikswo; John A McLean
Journal:  Anal Chem       Date:  2013-03-21       Impact factor: 6.986

9.  LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice.

Authors:  Thierry Touvier; Françoise Conte-Auriol; Olivier Briand; Céline Cudejko; Réjane Paumelle; Sandrine Caron; Eric Baugé; Yves Rouillé; Jean-Pierre Salles; Bart Staels; Bernard Bailleul
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

10.  Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes.

Authors:  Sandrine Caron; Carolina Huaman Samanez; Hélène Dehondt; Maheul Ploton; Olivier Briand; Fleur Lien; Emilie Dorchies; Julie Dumont; Catherine Postic; Bertrand Cariou; Philippe Lefebvre; Bart Staels
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.